CLAIMS

1. The compound (2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-trimethyl-ammonium xinafoate of formula (I)



(I)

2. A process for the preparation of the compound of formula (I) according to claim 1, by reacting the triazolone derivative of formula (II) with the xinafoate salt of formula (III)



said process comprising the steps of:

1) dissolving in water (2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-trimethyl-ammonium salt (II)



(II)

wherein X^- is an organic or inorganic anion

2) adding a solution of a xinafoate salt of formula (III)



(III)

wherein Y^+ is an alkaline or alkaline earth metal cation.

3. A process according to claim 2, which comprises a step 3) of washing the product obtained according to steps 1) and 2) with one or more aqueous or organic solvents.

4. A process according to claims 1 to 3, wherein X^- is bromide, methanesulfonate or acetate.

5. A process according to claims 1 to 4, wherein Y^+ is sodium or potassium.

6. A crystal form of a compound of formula (I), wherein said crystal form is characterized by at least one of the following XRPD peaks: 8.6, 9.9 and 23.2 ±0.2 degrees/2 theta [Cu Kα radiation (λ = 1.5406 Å)].

7. A crystal form according to claim 6, characterized by the following XRPD peaks: 8.6, 9.9, 10.7, 11.0 and 23.2 ±0.2 degrees/2 theta [Cu Kα radiation (λ = 1.5406 Å)].

8. A crystal form of a compound of formula (I) according to claims 6 and 7, characterized by the following XRPD peaks: 8.6, 9.9, 10.7, 11.0, 13.0, 15.3, 19.3, 19.7, 23.2 and

27.6 ±0.2 degrees/2 theta [Cu Kα radiation (λ = 1.5406 Å)].

9. A pharmaceutical composition comprising the compound of formula (I) and one or more pharmaceutically acceptable carriers and/or excipients.

10. A pharmaceutical composition comprising the crystal form of a compound of formula (I) according to claims 6, 7, or 8 and one or more pharmaceutically acceptable carriers and/or excipients.

11. A pharmaceutical composition according to claims 9 or 10, formulated in form of a dry powder.

12. The compound of formula (I) or the crystal form according to claims 6, 7 or 8 for use as a medicament.

13. The compound of formula (I) or the crystal form according to claims 6, 7 or 8 for use in the prevention and/or treatment of an inflammatory or obstructive respiratory disease.

14. The compound of formula (I) or the crystal form according to claims 6, 7 or 8 for use according to claim 13, wherein the inflammatory or obstructive respiratory diseases are selected from asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, idiopathic pulmonary fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, smoking-induced emphysema and cystic fibrosis.

15. The pharmaceutical composition according to any one of claims 9 to 11, for use in the prevention and/or treatment of an inflammatory or obstructive respiratory disease.

16. The pharmaceutical composition for use according to claim 15 wherein the inflammatory or obstructive respiratory diseases are selected from: asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, idiopathic pulmonary fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, smoking-induced emphysema and cystic fibrosis.

17. Use of the compound of formula (I) according to claim 1 or the crystal form according

to claim 6, 7 or 8 or the pharmaceutical composition according to any one of claims 9 to 11 in the manufacture of a medicament for prevention and/or treatment of an inflammatory or obstructive respiratory disease.

18. The use according to claim 17, wherein the inflammatory or obstructive respiratory diseases are selected from asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, idiopathic pulmonary fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, smoking-induced emphysema and cystic fibrosis.